LUNGevity Foundation
Dr. Brahmer's research and clinical practice focuses on the development of new therapies, including immunotherapies, for the treatment and prevention of lung cancer and mesothelioma. She was involved in the phase 1 trial of the PD-1 blocking antibody, nivolumab. Dr. Brahmer is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee.
This person is not in the org chart
This person is not in any offices
LUNGevity Foundation
2 followers
LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, policy initiatives, education, support, and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the disease—while promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivors—and those who help them live longer and better lives.